Interpace Biosciences, Inc. (IDXG) stock
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Earnings
Interpace Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Interpace Biosciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Jan 19, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 15, 2026before the open | – | – | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026after the close | $9.13M | -0.7% | $0.01 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026after the close | $9.00M | -21.7% | $0.03 | Release |
| Q4 FY2025ended Dec 31, 2025 | Jan 20, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025after the close | $8.80M | -28.4% | $0.03 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 8, 2025after the close | $9.20M | -23.3% | -$0.14 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $11.50M | – | $0.06 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | $12.30M | – | $0.29 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 2, 2024after the close | $12.00M | – | $0.46 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 13, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023after the close | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023during market hours | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 12, 2023after the close | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 27, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022after the close | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022after the close | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022after the close | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 31, 2022after the close | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021after the close | – | – | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 5, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 20, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 20, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | Jun 25, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Interpace Biosciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue | Q3 FY2026 | $10.10M – $10.40M | – | New | Oct 15, 2026 |
| full-year 2026 revenue | FY2026 | $40.00M | – | New | Jan 20, 2026 |
| year-over-year thyroid revenue growth | FY2026 | +16% | – | New | May 14, 2026 |
| growth in thyroid testing revenue | FY2026 | +16% | – | New | Jan 20, 2026 |
| thyroid revenue growth | FY2026 | +16% | – | Reaffirmed | Apr 1, 2026 |
Guidance history
Every forecast Interpace Biosciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 15, 2026 | revenue | Q3 FY2026 | $10.10M – $10.40M | New |
| May 14, 2026 | year-over-year thyroid revenue growth | FY2026 | +16% | New |
| Apr 1, 2026 | thyroid revenue growth | FY2026 | +16% | Reaffirmed |
| Jan 20, 2026 | growth in thyroid testing revenue | FY2026 | +16% | New |
| Jan 20, 2026 | full-year 2026 revenue | FY2026 | $40.00M | New |
| May 8, 2025 | revenue guidance | FY2025 | $38.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Interpace Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Results
- News
- News
- Results
- Update
See a number that looks wrong?